# Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients

> **NCT02221999** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 250 (estimated)

## Conditions studied

- Tubular Breast Cancer
- Mucinous Breast Cancer
- Invasive Ductal Breast Cancer
- Inflammatory Breast Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Cisplatin
- **DRUG:** Gonadotropin-releasing hormone agonist
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02221999
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-09
- **Primary completion:** 2019-01
- **Final completion:** 2029-01
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221999, "Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02221999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*